Aurobindo Pharma Ltd. (AUROPHARMA) — Tipsheet

Aurobindo gets FTC nod for Lannett, moves closing to June

Tipsheet Editorial — Fri, 19 Jun 2026 08:25:38 GMT

The US regulator clears a key hurdle for the generics deal announced last July. Aurobindo now expects to close before end of June, ahead of initial guidance.

What’s new

Aurobindo receives US FTC clearance for Lannett acquisition.
Closing now expected before end-June, ahead of early Q2 FY27 guidance.
Deal removes key regulatory hurdle for generics expansion.

Why it matters

The FTC approval de-risks Aurobindo's largest M&A move in years. With two plants under FDA OAI classification, the faster timeline signals confidence in integration. The deal strengthens its US generics presence, but regulatory headwinds at existing facilities remain a drag.

What we’re watching

Integration costs and margin impact from Lannett.
Lannett's revenue contribution and product pipeline.
Aurobindo's resolution of OAI designations at its plants.

The full read

Aurobindo Pharma cleared the last big regulatory hurdle for its Lannett acquisition. The US FTC approved the deal, announced in July 2025, and the company now expects to close before end-June — ahead of the early Q2 FY27 guidance. That matters because Aurobindo's US generics business has been under FDA scrutiny; two plants earned OAI designations in the past six months. The acquisition is meant to strengthen that business, but integration costs and ongoing regulatory overhang remain. The FTC nod removes deal uncertainty, but the real test is execution post-close.

Primary source: BSE · NSE

Aurobindo gets second OAI plant in six months

Tipsheet Editorial — Fri, 12 Jun 2026 18:18:26 GMT

Unit-III in Pashamylaram joins Unit-I on FDA's enforcement track after an inspection with 11 observations. Warning letter or import alert possible.

What’s new

US FDA classified Eugia Pharma's Unit-III facility as OAI after January–February 2026 inspection.
OAI signals serious violations and may precede warning letter or import restrictions.
This is the second OAI for Aurobindo this year; Unit-I received similar earlier.
Company states no immediate financial or operational impact.

Why it matters

Two OAI designations in six months suggest a pattern the US FDA is tracking. For a company with ₹84,742 cr market cap and heavy US generics exposure, even one plant under escalation restricts new approvals. The 'no immediate impact' line may hold for now, but the regulatory runway is narrowing.

What we’re watching

Whether FDA issues a warning letter or import alert for Unit-III.
Impact on ANDA approvals from this facility.
Remediation timeline and any reclassification.

The full read

Aurobindo Pharma's US generics business just took a second hit. The FDA classified the company's Unit-III formulation plant, operated by subsidiary Eugia Pharma, as Official Action Indicated after an 11-observation inspection in January–February 2026. That label, reserved for serious violations, puts the facility on track for a warning letter or even import restrictions. The sting: this follows a near-identical OAI at Unit-I earlier in the year. Aurobindo insists there's no immediate financial or operational impact, and at ₹84,742 cr market cap with ₹8,853 cr in quarterly sales, the company can absorb some disruption. But two OAI classifications in six months aren't a blip — they're a pattern. The open question is whether the FDA escalates enforcement, and how many pending ANDAs depend on these plants. The runway is narrowing.

Primary source: BSE · NSE

Aurobindo sees FY27 margins topping 21% after record ₹33,653 cr revenue year

Tipsheet Editorial — Fri, 22 May 2026 09:55:34 GMT

Management guided for EBITDA margins above 21% in FY27, up from FY26, with Pen-G integration and European scale-up as the main levers. Biosimilars revenue now pushed to 2028.

What’s new

FY26 revenue hit a record ₹33,653 crore; management guided FY27 EBITDA margin above 21%.
Biosimilars CDMO unit TheraNym now expects commercial revenue in 2028, not 2030 as previously indicated.
Lannett acquisition in the US likely to close early in Q2 FY27 after regulatory delays.

Why it matters

The margin guidance is the real signal. Aurobindo is linking its Pen-G backward integration to the next leg of margin improvement, a play that hinges on the European business crossing €1 billion in scale. The biosimilars delay is a trade-off: management is pushing the timeline out, which suggests slower-than-expected commercialization of TheraNym, a unit that was supposed to diversify Aurobindo beyond generics.

What we’re watching

Whether the Lannett deal actually closes in Q2 FY27, after the regulatory delays.
Pen-G external sales inflection — management flagged this as a margin driver, but execution details remain thin.
FY27 quarterly margins to see if the 21%+ target holds through the year.

The full read

Aurobindo's FY26 revenue crossed ₹33,653 crore, a record. The more important number in the concall was the 21% EBITDA margin guide for FY27, which implies meaningful improvement from the prior year. The company is tying that to Pen-G backward integration and a European business that now sits at €1 billion. Both are structural, not one-offs, so the guide has some credibility if the integration stays on track. The biosimilars timeline, however, moved in the wrong direction. TheraNym's commercial revenue is now pushed to 2028, a year later than previously forecast, which is a clear signal that the unit is not yet a near-term growth driver. And the Lannett acquisition, which was supposed to strengthen Aurobindo's US portfolio, is still sitting in regulatory limbo. The company now expects it to close early in Q2 FY27, after delays. The concall had one clear message: Aurobindo is betting that scale and integration will lift margins. The open question is whether biosimilars and the US business can deliver the other half of the growth story.

Primary source: BSE · NSE

Aurobindo’s FY26 audited results are a formality. Profit growth is 0.6%.

Tipsheet Editorial — Thu, 21 May 2026 22:44:16 GMT

The board approved audited numbers already public via a May press release. Consolidated PAT for the full year rose 0.6% to ₹35,030 crore.

What’s new

Board approved audited Q4 and FY26 results; numbers were already public via a prior May press release.
Consolidated PAT: ₹9,208 cr in Q4 (+0.5% YoY), ₹35,030 cr for FY26 (+0.6% YoY).
Routine auditor changes: secretarial auditors resigned, new ones appointed, internal auditors reappointed.

Why it matters

This is a compliance filing for numbers the market has already digested. The 0.6% full-year profit growth is negligible for a company of this scale, confirming a year of near-zero earnings momentum. The governance changes are procedural and add no new financial signal.

What we’re watching

FY27 guidance or commentary from management on growth drivers.
Margin trends in the API and formulations businesses.
Any new capital allocation plans announced alongside these audited results.

The full read

Aurobindo’s audited FY26 results are a formality. The numbers, which the market has had since May, show consolidated profit of ₹35,030 crore — up just 0.6% year-on-year. Q4 profit of ₹9,208 crore tells the same story: growth of 0.5% is noise. The board also approved the resignation of one set of secretarial auditors and the appointment of another, plus the reappointment of internal auditors. These are procedural housekeeping items. There is no new strategic or financial information in this filing.

Primary source: BSE · NSE

Aurobindo's TheraNym to build a drug plant for MSD, capex up to $175M

Tipsheet Editorial — Thu, 21 May 2026 20:49:54 GMT

A new greenfield facility for Merck Sharp & Dohme is the sharpest detail in an otherwise routine earnings recap.

What’s new

TheraNym signed an additional schedule with MSD to build a greenfield drug substance facility.
The facility's estimated capital expenditure is US$150-175 million.
CuraTeQ completed Phase 3 for Omalizumab and will file Denosumab with the EMA by Q2 2026.

Why it matters

A greenfield build for a single client is a concrete capital bet, not a speculative pipeline slide. It deepens a committed partnership with one of the world's largest drug makers and anchors the biologics subsidiary with a physical asset.

What we’re watching

Details on the financing mix and construction timeline for the US$150-175M plant.
The EMA filing decision for Denosumab by Q2 2026.
Execution against the target of 15 biosimilars in a US$50B market by 2030.

The full read

Aurobindo's Q4 presentation was a recap of known results. Revenue of ₹8,853 crore was up 5.6%, net profit of ₹921 crore was up 2%. The new detail is a US$150-175 million capex commitment through biosimilars subsidiary TheraNym. The company will build a greenfield drug substance plant for MSD. Separately, CuraTeQ completed Phase 3 for Omalizumab and is targeting a Q2 2026 EMA filing for Denosumab. Aurobindo now has 15 biosimilars in development, aiming at what it calls a US$50 billion addressable market by 2030. The plant deal is the material update. It commits a large sum to a single client relationship. Routine earnings. One new plant.

Primary source: BSE · NSE

Aurobindo's FY26 revenue grows 5.6%, profit up 2%

Tipsheet Editorial — Thu, 21 May 2026 20:47:02 GMT

The Indian drugmaker's audited annual results show modest, steady growth. No guidance changes, no surprises.

What’s new

Consolidated revenue for FY26 rose 5.6% year-on-year.
Net profit grew 2% year-on-year for the full year.
European business crossed €1 billion in annual revenue; margins were steady.

Why it matters

This is a standard, anticipated results release for a large-cap pharmaceutical company. The growth is modest, the margins are flat, and the press release offers no new strategic direction. For investors, it confirms the company is on its existing course without adding new information.

What we’re watching

Any new commentary on the US generics pipeline from the concall.
How the European segment performs after crossing the €1bn revenue mark.
Whether margin pressure emerges in future quarters.

The full read

Aurobindo Pharma's audited FY26 results show consolidated revenue up 5.6% year-on-year and net profit up 2%. The European business crossed €1 billion in annual revenue, with margins described as steady. Hardly anything else changed. The modest top-line growth and flat profit expansion suggest a steady but unspectacular year. This is a routine update for a large-cap drugmaker. The numbers were anticipated, and they arrived on cue.

Primary source: BSE · NSE

Aurobindo's Q4 profit grew. That's the job.

Tipsheet Editorial — Thu, 21 May 2026 19:44:37 GMT

A routine earnings release. The board signed off on FY26 numbers showing sequential and year-on-year profit gains, with no new guidance.

What’s new

Board approved audited financial results for Q4 and FY26.
Results show sequential and year-on-year profit growth.
No material new information or guidance beyond the standard numbers.

Why it matters

This is a procedural disclosure for a large-cap company. The market anticipates these results, and the core information is not a surprise. The absence of new guidance or strategic announcements means the filing only confirms what was already expected.

What we’re watching

Management commentary on API pricing and US market demand during the concall.
Analyst model revisions based on the reported numbers.
The stock's reaction to a known quantity.

The full read

Aurobindo's board met. It signed off on the audited numbers for Q4 and FY26. The results show profit growth on both a sequential and year-on-year basis, which is the baseline expectation for a company of this scale. The filing contains no new strategic direction, no revised guidance, and no surprise. It's a procedural disclosure. What matters now isn't the numbers themselves. It's the commentary on the subsequent concall, where management may address API pricing dynamics and US market demand. The event is scored a 5 out of 10, squarely in the routine category. Three quarters in a row, the script has held.

Primary source: BSE · NSE